Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
33 results about "Chronic phase chronic myelogenous leukemia" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Chronic phase chronic myelogenous leukemia is a phase of chronic myelogenous leukemia in which 5% or fewer of the cells in the blood and bone marrow are blast cells (immature blood cells). This phase may last from several months to several years, and there may be no symptoms of leukemia.
Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases
Compounds of the present invention, alone and in combination with other active agents, find utility in the treatment of hyperproliferative diseases, mammalian cancers and especially human cancers including but not limited to for example malignant melanomas, myeloproliferative diseases, chronic myelogenous leukemia, acute lymphocytic leukemia, a disease caused by c-ABL kinase, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs thereof.
Owner:DECIPHERA PHARMA LLC
Substituted heterocyclic compounds and methods of use
The present invention relates to pyridines, pyrimidines and derivatives thereof, and pharmaceutically acceptable salts thereof. Also included is a method of treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic β cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount a compound as described above.
Owner:AMGEN INC
T cell receptor-like antibodies specific for a WT1 peptide presented by HLA-A2
The present invention provides antigen binding proteins that specifically bind to Wilms' tumor protein (WT1), including humanized, chimeric and fully human antibodies against WT1, antibody fragments, chimeric antigen receptors (CARs), fusion proteins, and conjugates thereof. The antigen binding proteins and antibodies bind to HLA-A0201-restricted WT1 peptide. Such antibodies, fragments, fusion proteins and conjugates thereof are useful for the treatment of WT1 associated cancers, including for example, breast cancer, ovarian cancer, prostate cancer, chronic myelocytic leukemia, multiple myeloma, acute lymphoblastic leukemia (ALL), acute myeloid / myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). In more particular embodiments, the anti-WT1 / A antibodies may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and / or expression levels.
Owner:EUREKA THERAPEUTICS INC +1
Methods for treating hematological disorders through inhibition of DNA methylation and histone deacetylase
InactiveUS20050159347A1Address bad outcomesReduce dosageAntibacterial agentsBiocideCyclic peptideHydroxamic acid
Methods are provided for treating hematological disorders by inhibition of DNA hypomethylation and histone deacetylase. Such disorders include, for example, acute promyelocytic leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, myelodysplastic syndromes, and sickle cell anemia. The methods comprise: administering to a patient suffering from the disease a therapeutically effective amount of a DNA methylation inhibitor such as a cysteine analog such as decitabine, in combination with an effective amount of histone deacetylase inhibitor such as hydroxamic acid, cyclic peptide, benzamide, butyrate, and depudecin.
Owner:SUPERGEN
Composite profiles of cell antigens and target signal transduction proteins for analysis and clinical management of hematologic cancers
InactiveUS20070105165A1Increased relapse riskDetermining prognosisDisease diagnosisBlood/immune system cellsCellular antigensTarget signal
The present invention is directed to methods for establishing a composite marker profile for a sample derived from an individual suspected having a neoplastic condition. A composite marker profile of the invention allows for identification of prognostically and therapeutically relevant subgroups of neoplastic conditions and prediction of the clinical course of an individual. The methods of the invention provide tools useful in choosing a therapy for an individual afflicted with a neoplastic condition, including methods for assigning a risk group, methods of predicting an increased risk of relapse, methods of predicting an increased risk of developing secondary complications, methods of choosing a therapy for an individual, methods of determining the efficacy of a therapy in an individual, and methods of determining the prognosis for an individual. In particular, the method of the present invention discloses a method for establishing a composite marker profile that can serve as a prognostic indicator to predict whether the course of a neoplastic condition in a individual will be aggressive or indolent, thereby aiding the clinician in managing the patient and evaluating the modality of treatment to be used. In particular embodiments disclosed herein, the methods of the invention are directed to establishing a composite marker profile for a leukemia selected from the group consisting of Chronic Lymphocytic Leukemia (CLL), Acute Myelogenous Leukemia (AML), Chronic Myelogenous Leukemia (CML), and Acute Lymphocytic Leukemia (ALL).
Owner:BECKMAN COULTER INC +4
Heterocyclic compounds and their uses
ActiveUS8193199B2Low inhibitory potencyInhibitory activityBiocideSenses disorderMyeloid leukemiaB-cell acute lymphoblastic leukaemia
Substituted bicyclic heteroaryls having the structures:and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.
Owner:AMGEN INC
Substituted heterocyclic compounds and methods of use
The present invention relates to compounds having the general formula or a pharmaceutically acceptable salt thereof, wherein R1 is a saturated or unsaturated 5-, 6- or 7-membered, ring containing 0, 1, 2 or 3 atoms selected from N, O and S, wherein the ring may be fused with a benzo group, and is substituted by 0, 1 or 2 oxo groups, and wherein R1 is additionally substituted; and R2 is a substituted C1-6alkyl. Also included is a method of prophylaxis or treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic β cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount a compound as described above.
Owner:AMGEN INC
Indirubin derivatives, and uses thereof
Indirubin is the major active anti-tumor component of a traditional Chinese herbal medicine used for treatment of chronic myelogenous leukemia (CML). Indirubin derivatives (IRDs) potently reduce the viabilities of various cancer cells and affect kinase activities. IRDs disclosed herein provide new therapeutics for cancer and conditions regulated by the kinase activities.
Owner:CITY OF HOPE +1
Herbal composition for treating CD33+ acute and chronic myeloid leukemia and a method thereof
InactiveUS20030049334A1Simple methodReduced viabilityBiocideOrganic active ingredientsMyeloid leukemiaMedicine
The present invention relates to a method of treating CD33+ acute and chronic myeloid leukemia in animals including humans, using fraction nos. 1 and 9 obtained from water:methanol fraction by column chromatography, with ratio of water and methanol ranging between 1:5 to 5:1, wherein said water:methanol fraction is obtained from the polar extract of piper betel by HPLC, with retention time of 3.6 and 24.0 minutes respectively, with said fractions used both individually, and in combination, and a composition comprising the said fraction nos. 1 and 9.
Owner:COUNCIL OF SCI & IND RES INDIAN REGISTERED BODY INC UNDER THE REGISTRATION SOCIES ACT ACT XXI OF 1860
Process for preparing N-phenyl-2-pyrimidyl amine derivative
The present invention relates to new organic compound, and is especially the preparation process of N-(2-methyl-5-nitro) phenyl-4-(3-pyridyl) pyrimidiyl-2-amine as the key intermediate for imatinib, which is tyrosine protein kinase inhibitor for treating chronic myeloid leukemia and other diseases, and its analog N- phenyl-pyrimidiyl-2-amine derivative. The target product may be prepared through condensation of 4-aromatic heterocycle-2-halogenated pyrimidine and substituted aniline in the presence of catalyst. The preparation process has low material cost, scientific synthesis path, high product yield and other advantages.
Owner:ZHEJIANG ACAD OF MEDICAL SCI
Substituted heterocyclic compounds and methods of use
The present invention relates to compounds having the general formula or a pharmaceutically acceptable salt thereof, wherein R1 is a saturated or unsaturated 5-, 6- or 7-membered, ring containing 0, 1, 2 or 3 atoms selected from N, 0 and S, wherein the ring may be fused with a benzo group, and is substituted by 0, 1 or 2 oxo groups, and wherein R1 is additionally substituted; and R2 is a substituted C1-6alkyl. Also included is a method of prophylaxis or treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic β cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount a compound as described above.
Owner:AMGEN INC
Thiazoleamide compound and use thereof for the preparation of anti-malignant tumor medicines
InactiveCN101948467AReduce first pass effectImprove bioavailabilityOrganic active ingredientsOrganic chemistryMyeloid leukemiaSide effect
The invention relates to a thiazoleamide compound and a use thereof for the preparation of anti-malignant tumor medicines. As an ideal Bcr-Abl and Src protein tyrosine kinase inhibitor, the thiazoleamide compound according to the invention shows outstanding effect when being used for chronic myeloid leukemia, acute myeloid leukemia, acute lymphoblastic leukemia, myeloproliferative syndrome, lung cancer, ovarian cancer, prostatic cancer, soft tissue sarcoma, malignant glioma and other malignant tumors, and simultaneously has the advantages of small dose and side effect.
Owner:苏州得普医药科技有限公司
Glycyrrhetinic acid-hydrogen sulfide donor reagent derivative, and synthetic method and application thereof
InactiveCN106243182AInhibitory activity hasNovel structureOrganic active ingredientsSteroidsSolventLeukemia
The invention discloses a glycyrrhetinic acid-hydrogen sulfide donor reagent derivative, and a synthetic method and an application thereof. The synthetic method of the derivative comprises the following steps: carrying out a reaction on glycyrrhetinic acid, alpha,omega-dibromoalkane and an alkali in an aprotic polar solvent to obtain a compound 1; and carrying out a reaction on the compound 1, a hydrogen sulfide donor and the alkali in the aprotic polar solvent to obtain a crude target product, wherein the reactions are carried out under heating or non-heating conditions. Most compounds in the synthesized derivative have certain inhibition activity to a chronic marrow leukemia cell K562, and are hopeful to be used in the preparation of corresponding antitumor medicines and chronic marrow leukemia cell treatment medicines. The synthesized derivative has a structure represented by general formula (I) shown in the description; and in the general formula (I), n is 2-8, and R is one of three formulas shown in the description.
Owner:GUANGXI NORMAL UNIV
Process for preparing N-phenyl-2-pyrimidyl amine derivative
Owner:ZHEJIANG ACAD OF MEDICAL SCI
Thiazoleamide compound and medical application thereof in treating malignant tumor
InactiveCN101967142AReduce first pass effectImprove bioavailabilityOrganic active ingredientsOrganic chemistrySide effectMyeloid leukemia
The invention relates to a thiazoleamide compound and medical application thereof in treating malignant tumor. The thiazoleamide compound is an ideal Bcr-Abl and Src protein tyrosine kinase inhibitor and shows favorable effects when used for treating the malignant tumors, such as chronic myeloid leukemia, acute myeloid leukemia, acute lymphocytic leukemia, myelodysplastic syndromes, lung cancers, ovarian cancers, prostatic cancers, soft tissue sarcomas, malignant gliomas, and the like, and meanwhile, the thiazoleamide compound has the advantages of less usage amount and side effect.
Owner:苏州得普医药科技有限公司
Glycyrrhetinic acid-hydrogen sulfide donor reagent derivative and its synthesis method and application
InactiveCN106243182BInhibitory activity hasNovel structureOrganic active ingredientsSteroidsSynthesis methodsSolvent
The invention discloses a glycyrrhetinic acid-hydrogen sulfide donor reagent derivative, and a synthetic method and an application thereof. The synthetic method of the derivative comprises the following steps: carrying out a reaction on glycyrrhetinic acid, alpha,omega-dibromoalkane and an alkali in an aprotic polar solvent to obtain a compound 1; and carrying out a reaction on the compound 1, a hydrogen sulfide donor and the alkali in the aprotic polar solvent to obtain a crude target product, wherein the reactions are carried out under heating or non-heating conditions. Most compounds in the synthesized derivative have certain inhibition activity to a chronic marrow leukemia cell K562, and are hopeful to be used in the preparation of corresponding antitumor medicines and chronic marrow leukemia cell treatment medicines. The synthesized derivative has a structure represented by general formula (I) shown in the description; and in the general formula (I), n is 2-8, and R is one of three formulas shown in the description.
Owner:GUANGXI NORMAL UNIV
Substituted heterocyclic compounds and methods of use
The present invention relates to pyrimidinones and pyridones and derivatives thereof, and pharmaceutically acceptable salts thereof. Also included is a method of treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic β cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount a compound as described above.
Owner:AMGEN INC
Substituted heterocyclic compounds and methods of use
The present invention relates to pyrimidinones and pyridones and derivatives thereof, and pharmaceutically acceptable salts thereof. Also included is a method of treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic β cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount a compound as described above.
Owner:AMGEN INC
Indirubin derivatives and uses thereof in treating chronic myelogenous leukemia
Owner:CITY OF HOPE +1
Combination of lenalidomide or pomalidomide and CD38 antibody-attenuated interferon-alpha constructs, and the use thereof
Methods for cancer treatment include administering to a cancer patient an anti- CD38 antibody-attenuated human IFN alpha-2b construct and lenalidomide or pomalidomide. Tumors that may be treated according to these methods include tumors which comprise CD-38 expressing tumor cells, including B-cell lymphoma, multiple myeloma, non-Hodgkin's lymphoma, chronic myelogenous leukemia, chronic lymphocytic leukemia, and acute lymphocytic leukemia.
Owner:TEVA PHARMA AUSTRALIA PTY LTD
Compounds and compositions as inhibitors of protein kinases
The invention provides small molecule heteroaromatic compounds that are ATP-competitive tyrosine kinase inhibitors displaying a significant inhibitory potency towards resistant T315I ABL mutants. The compounds of the invention find a useful application in the treatment of BCR-ABL inhibitor resistant diseases, such as imatinib resistant chronic myelogenous leukemia.
Owner:PANG WAI KIT +1
Chimeric antigen receptor T cell targeted to WT1 and application of chimeric antigen receptor T cell
InactiveCN108676098ASimple structureEasy to makeImmunoglobulin superfamilyMicrobiological testing/measurementCancer cellMyeloid leukemia
The invention discloses a chimeric antigen receptor T cell targeted to WT1 and application of the chimeric antigen receptor T cell, and belongs to the technical field of genetic engineering. The chimeric antigen receptor T cell comprises an antigen binding area ScFv and a signal transduction area CD28-CD zeta, connected in series in sequence; and the amino acid sequence of the chimeric antigen receptor T cell is as shown in SEQ ID NO. 1. The chimeric antigen receptor T cell targeted to WT1 has high tumor-killing activity on a cancer cell for expressing TEM8, especially a cancer for expressingWT1, such as chronic myeloid leukemia and lymphoma for expressing WT1.
Owner:段海峰
Indole derivative containing diazole, triazole and pyrazole structural units and application thereof
ActiveCN113754649AGood tumor suppressor activityHigh activityOrganic active ingredientsOrganic chemistryProstate cancer cellMyeloid leukemia
The invention relates to an indole derivative structure containing diazole, triazole and pyrazole structural units and application of the indole derivative structure. The compound has a structure as shown in a general formula (I), wherein X is O, S or N-NH2. Indole is used as a mother nucleus, pyrazole is introduced to the site 3, a series of indole derivatives containing diazole, triazole and pyrazole structures are synthesized, and the compounds have good cytotoxicity to human liver cancer cells HepG2, human non-small cell lung cancer cells A549, human prostate cancer cells PC-3 and human chronic myeloid leukemia cells K562.
Owner:GUIZHOU UNIV
Spirostanol saponins and application thereof
The invention discloses spirostanol saponins and application thereof. The spirostanol saponins is extracted and separated from tupistra chinensis rhizomes. The spirostanol saponins and the application have the advantages that as discovered in experimental research, excellent effects can be realized by nine types of spirostanol saponins in the aspects of cancer prevention and anti-inflammation actions, certain suppression effects can be realized by the spirostanol saponins for pharynx squamous cell carcinoma, pharynx cancer, nasopharyngeal squamous cell carcinoma, liver cancer, chronic myelocytic leukemia, lung adenocarcinoma and the like, and accordingly the spirostanol saponins is high in efficiency and low in toxicity and can be hopefully developed to obtain novel anticancer medicines and healthcare foods.
Owner:GUANGDONG PHARMA UNIV
Method for multiplex-detecting chronic myelogenous leukemia gene using cleavable probe
ActiveUS9512488B2Sure easySmall amountMicrobiological testing/measurementFermentationChronic myelogenous leukemiaGene expression
One embodiment of the present invention provides a detection kit for detecting a chronic myelogenous leukemia (CML) gene expression, wherein the detection kit includes a primer set which is specifically bound to the CML gene; and a cleavable probe which is specifically bound to the inside of a CML gene amplification product which is amplified by the primer set. Another embodiment of the present invention provides a method of measuring the CML gene expression by using the detection kit according to one embodiment of the present invention. The method according to one embodiment of the present invention is used to efficiently detect a low CML gene expression for CML diagnosis and prognosis diagnosis.
Owner:SAMSUNG LIFE PUBLIC WELFARE FOUND
Allosteric inhibitors of thymidylate synthase
The current invention is directed to a class of compounds that inhibit the function of Thymidylate synthase. Thymidylate synthase inhibition was noted to result in inhibition of tumor cell grow and killing of tumor cells. Thymidylate synthase inhibition is, thus, useful for treatment of various types of cancers, including but not limited to, acute lymphoblatic leukemia (ALL), acute myelogenous leukemia (AML), acute promyelocytic leukemia, chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), acute monocytic leukemia (AMOL), hairy cell leukemia, large cell immunoblastic lymphoma, plasmacytoma, multiple myeloma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, leukemia, brain cancer, lung cancer, central nervous system (CNS) cancer, melanoma, renal cancer, prostate cancer, colon cancer, ovarian cancer and breast cancer. The compounds disclosed herein can be used alone or in combination with other cancer treatment regimens (e.g., radiation therapy and / or other chemotherapeutic agents that are administered to a subject having a tumor, cancer or neoplasia).
Owner:UNIV OF FLORIDA RES FOUNDATION INC
4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML)
InactiveCN1874776AOrganic active ingredientsOrganic chemistryChronic myelogenous leukemia4-Anilino-3-quinolinecarbonitrile
Compounds of formula (I) wherein n is an integer from 1-3; X is N, CH, provided that when X is N, n is 2 or 3; R is alkyl of 1 to 3 carbon atoms; R<1> is 2,4-diCI, 5-OMe; 2,4-diCI; 3,4,5-triOMe; 3-CI, 5-OMe; 2-Me, 5-OMe; 2,4-di-Me; 2,4-diMe-5-OMe, 2,4-diCI, 5-OEt; R<2> is alkyl of 1 to 2 carbon atoms, and pharmaceutically acceptable salts thereof are useful for the treatment of chronic myelogenous leukemia (CML).
Owner:WYETH LLC
Application of drug containing catechin to preparation of drug for preventing and/or treating leukemia
InactiveCN105213368AWide range of treatmentPrevent proliferationOrganic active ingredientsAntineoplastic agentsMyeloid leukemiaSide effect
The invention provides an application of a drug containing catechin or polymorphic bodies to preparation of a drug for preventing and / or treating leukemia. In vivo experiment research shows that the catechin can significantly inhibit proliferation of related leukemic cells after being orally taken or injected; in vitro experiment research shows that the catechin can inhibit growth of leukemic cells. The catechin has wider treatment range for leukemia and has exact treatment effects on leukemia including lymphocytic leukemia, reticulocyte leukemia, chromic myeloid leukemia and the like. Meanwhile, toxic and side effects are not discovered, so that the drug has prominent promotion prospect.
Owner:王孝仓
Compounds for treating rac-gtpase mediated disorder
PendingCN107849033AOrganic active ingredientsOrganic chemistryLymphocytes.immatureChronic myelogenous leukemia
This disclosure relates to compositions including certain compounds identified by a quantitative, high throughput assay to be effective in the treatment of a Rac-GTPase mediated disorder (e.g., acutelymphoblastic or chronic myelogenous leukemia), as well as methods for the manufacture of and the use of these compounds for treating a Rac-GTPase mediated disorder.
Owner:CHILDRENS MEDICAL CENT CORP
Pharmaceutical composition for preventing or treating chronic myeloid leukemia and method using the same
ActiveCN107257685AHalogenated hydrocarbon active ingredientsOrganic chemistryMyeloid leukemiaOncology
Provided are a pharmaceutical composition for preventing or treating chronic myeloid leukemia and a method of preventing or treating chronic myeloid leukemia using the same, thereby being effectively applied to the prevention or treatment of chronic myeloid leukemia.
Owner:メドパクトインコーポレーテッド
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com